title: The C-terminus of human nucleotide receptor P2X7 is critical for receptor oligomerization and N-linked glycosylation.
abstract: BACKGROUND
  The P2X7 receptor binds extracellular ATP to mediate numerous inflammatory responses and is considered a potential biomarker and therapeutic target for diverse inflammatory and neurological diseases. P2X7 contains many single nucleotide polymorphisms, including several mutations located within its intracellular C-terminal trafficking domain. Mutations within the trafficking domain result in attenuated receptor activity and cell surface presentation, but the mechanisms by which amino acid changes within this region promote altered P2X7 function have not been elucidated.
  
  
  RESULTS
  We analyzed the amino acid sequence of P2X7 for any potential trafficking signals and found that P2X7 contains putative Arg-X-Arg ER retention sequences. Alanine substitutions near or within these sequences were constructed, and we determined that single mutation of R574 and R578 but not R576 or K579 attenuates P2X7-stimulated activation of ERK1/2 and induction of the transcription factors FosB and ΔFosB. We found that mutation of R578 within the trafficking domain to the naturally occurring Gln substitution disrupts P2X7 localization at the plasma membrane and results in R578Q displaying a higher apparent molecular weight in comparison to wild-type receptor. We used the glycosidase endoglycosidase H to determine that this difference in mass is due in part to the R578Q mutant possessing a larger mass of oligosaccharides, indicative of improper N-linked glycosylation addition and/or trimming. Chemical cross-linking experiments were also performed and suggest that the R578Q variant also does not form trimers as well as wild-type receptor, a function required for its full activity.
  
  
  CONCLUSIONS
  These data demonstrate the distal C-terminus of P2X7 is important for oligomerization and post-translational modification of the receptor, providing a mechanism by which mutations in the trafficking domain disrupt P2X7 activity and localization at the plasma membrane.
authors.affiliation: Department of Biomolecular Chemistry, The University of Wisconsin-Madison, Madison, Wisconsin, USA.
authors.forename: Lisa E
authors.initials: LE
authors.lastname: Wickert
authors.forename: Joshua B
authors.initials: JB
authors.lastname: Blanchette
authors.forename: Noelle V
authors.initials: NV
authors.lastname: Waldschmidt
authors.forename: Paul J
authors.initials: PJ
authors.lastname: Bertics
authors.forename: John M
authors.initials: JM
authors.lastname: Denu
authors.forename: Loren C
authors.initials: LC
authors.lastname: Denlinger
authors.forename: Lisa Y
authors.initials: LY
authors.lastname: Lenertz
mesh_terms: D000255:Adenosine Triphosphate / Q000031:analogs & derivatives / Q000494:pharmacology; D002462:Cell Membrane / Q000187:drug effects / Q000378:metabolism; D004721:Endoplasmic Reticulum / Q000187:drug effects / Q000378:metabolism; D006031:Glycosylation; D057809:HEK293 Cells; D006801:Humans; D009154:Mutation; D009584:Nitrogen / Q000378:metabolism*; D020641:Polymorphism, Single Nucleotide; D016062:Porosity; D055503:Protein Multimerization / Q000187:drug effects; D011499:Protein Processing, Post-Translational / Q000187:drug effects; D020836:Protein Structure, Quaternary; D017434:Protein Structure, Tertiary; D021381:Protein Transport / Q000187:drug effects; D058486:Receptors, Purinergic P2X7 / Q000737:chemistry* / Q000235:genetics / Q000378:metabolism*; D015398:Signal Transduction / Q000187:drug effects
chemical_list: D058486:Receptors, Purinergic P2X7; C033901:3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate; D000255:Adenosine Triphosphate; D009584:Nitrogen